As an RNA-binding protein, insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) is involved in enhancing the progression of a few malignant tumors by recognizing N6-methyladenosine on targeted RNA. However, the specific effects of IGF2BP2 on gastric cancer (GC) and the underlying mechanisms remain unclear. In this study, the expression level of IGF2BP2 was evaluated by analyzing data from a public database and performing immunohistochemical staining with GC specimens. The effect of IGF2BP2 on GC cell metastasis was investigated by Transwell assays and animal studies. RNA immunoprecipitation (RIP) was performed to identify potential mRNA bound to IGF2BP2. The levels of these identified RNAs were measured by RT-PCR, while corresponding proteins were quantified via Western blot. It was revealed that IGF2BP2 expression in GC tissues was significantly upregulated, and its overexpression was significantly associated with worse survival in GC patients. The aberrant expression of IGF2BP2 was demonstrated to promote the invasion and metastasis of GC cells by both in vivo and in vitro experiments. In subsequent experiments, it was then verified that by directly interacting with HMGA1 mRNA, IGF2BP2 augmented its stability and thus increased its expression. The knocking down of IGF2BP2 could significantly decrease the migration and invasion of GC cells, which could be reversed by increasing HMGA1 expression. Additionally, both in vitro and in vivo epithelial–mesenchymal transition (EMT) of GC cells were enhanced by IGF2BP2/HMGA1 axis. In conclusion, it was proven in our study that the IGF2BP2/HMGA1/EMT axis contributed to GC metastasis, suggesting its potential as a novel predictive and therapeutic biomarker for GC.

Background: Neoadjuvant chemotherapy is important to improve the prognosis of patients with advanced gastric cancer. However, it may result in postoperative complications (POCs). The aim of this study is to evaluate risk factors and prognostic impact of POCs in patients receiving neoadjuvant chemotherapy. Methods: We retrospectively collected clinical information of patients who underwent curative gastrectomy after receiving neoadjuvant chemotherapy between 2011 and 2018. Overall survival (OS) was analyzed using the Kaplan–Meier method. Logistic regression and Fisher’s exact test were used to evaluate risk factors for complications. Results: A total of 176 patients were included in our study. The 3-year OS rates for the complication group (n = 30) and non-complication group (n = 146) were 36.7% and 52.7%, respectively (p = 0.0294). Age, BMI, multivisceral resection and operation time were independent risk factors for POCs in patients. Patients with multivisceral resection were more likely to suffer from grade III-IV complications (p = 0.026). Inflammation complications might occur in patients with high BMI (p = 0.017). Low preoperative albumin seemed to be a risk factor for leakage complications (p = 0.033). Conclusions: Our study revealed that patients with POCs had a poor prognosis and we identified the risk factors for complications so that POCs can be avoided in time.

Background: To establish a systematic review and meta-analysis of all eligible studies to assess the diagnostic value of magnetically controlled capsule endoscopy (MCCE) in gastric diseases. Methods: All published studies identified by search in Medline, EMBASE, The Cochrane Library databases and Web of Science were meta-analyzed. Conventional gastroduodenoscopy (CG) regarded as the golden standard of diagnosis. A pooled sensitivity, specificity, diagnostic odds ratio (DOR) and summary receiver operating characteristic curve (SROC) and corresponding 95% confidence region were calculated to estimate the overall accuracy by using the bivariate mixed-effects binary regression models. Bias of involved studies was evaluated according to the quality assessment of diagnostic accuracy studies (QUADAS-2). Results: Of 832 studies, four studies from 2013 to 2019 meeting the inclusion criteria provided sufficient data (n=612). The pooled sensitivity, specificity and DOR were 91% (95% CI, 0.87–0.93), 90% (95% CI, 0.75–0.96) and 87.20 (95% CI, 27.38–277.74), respectively. The area under curve of SROC was 91% (95% CI, 0.88–0.94). Only few mild adverse events were observed. Conclusions: MCCE has a high sensitivity (91%) and specificity (90%) in diagnosis of gastric disease, The AUC and DOR of MCCE was 0.91 and 87.2. In conclusion, MCCE shows acceptable sensitivity and specificity for the diagnosis of gastric diseases in adults.

Despite of technological improvements in surgical equipment, anastomotic leakage (AL) after anterior rectal resection is still the most important and common complication in laparoscopy and open surgery. According to reports, the clinically obvious leakage rate after laparoscopic anterior rectal resection is 3–19%. AL is associated with high morbidity and mortality, and usually requires re-operation with stoma creation. It significantly increases the length of hospital stay and rehabilitation costs. For a long time, there has been controversy about the role of protective stomas, and there are still controversies. Some authors recommend the routine use of temporary stomas to reduce the incidence and incidence of AL. On the contrary, other authors discourage the regular use of temporary stomas, and preferring selective use. For these authors, a protective stoma can only reduce the catastrophic clinical consequences of AL and decrease the burden of stoma-related complications. The conventional method of temporarily using the stoma reduces the advantages of the laparoscopic technique, so it is advisable to use it selectively. The difficulty in choosing to use temporary stoma is related to the necessity of effective anastomotic cracking risk stratification, which is not yet available today. In this article, we reviewed literatures regarding the indications of prophylactic ostomy, stoma-associated complications, timing of reversal, and surgical complications, aimed at providing useful summary of experience for early stoma closure, and thus reduce stoma-associated complications and ultimately improve the quality of life of patients.

Gastric cancer, one of the deadliest gastrointestinal tumors, has a high incidence rate worldwide. Many studies show that the glycosyltransferase 8 domain-containing protein 1 (GLT8D1) plays a crucial role in protein glycosylation. However, few scholars have explored the prognostic importance of GLT8D1 in gastric cancer. The purpose of this research is to investigate the clinical value and biological function of GLT8D1 by examining multiple databases and performing relevant experiments. This study obtained the transcriptomic information and clinically relevant data from the cancer genome atlas (TCGA) and evaluated GLT8D1 in pan-cancer and gastric cancer. The prognostic role of GLT8D1 in the TCGA-stomach adenocarcinoma (STAD) dataset and gastric cancer patients was explored. A predictive nomogram was developed based on GLT8D1 mRNA expression level and clinical features. The receiver operating characteristic curve (ROC) values of predicting overall survival probabilities in the training set (TCGA-STAD dataset) and external validation sets (GSE62254 and FAHSYSU's cohort) were investigated to evaluate the performance of the prognostic nomogram. The STRING database and GeneMANIA were used to describe the proteins and genes interacting with GLT8D1. Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene ontology (GO), and gene set enrichment analysis (GSEA) were used to analyze the biological function of GLT8D1 based on the TCGA-STAD dataset. The study also performed in vitro assays to evaluate the proliferation, invasion, and migration abilities of GLT8D1 in gastric cancer cells. The results found that GLT8D1 is upregulated in gastric cancer. In addition, according to the study, those with stomach cancer who had increased GLT8D1 expression had decreased overall survival (OS). Moreover, GLT8D1 was identified as a separate risk factor for OS in gastric cancer by the univariate and multivariate analyses. Nomogram evaluation revealed that the predictive model was reliable for estimating the probability of overall survival over 1, 3, and 5 years. Functional enrichment analysis showed that interferon-γ response, mTORC1 signaling pathway, glycolysis, and IL6-JAK-STAT3 signaling pathways were enriched in patients with high GLT8D1 expression levels. Our in vitro assay experiment revealed that GLT8D1 promotes gastric cancer cell invasion and migration, which suggests the involvement of activating the IL6/STAT3 signaling pathway. The study concludes that GLT8D1 is a prognostic biomarker that suggests an unfavorable prognosis for gastric cancer.